Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Roche halts phase III trial of aleglitazar following safety review

July 11, 2013

Xoma presents preclinical results for novel IR allosteric monoclonal antibodies

July 11, 2013

Omthera Pharmaceuticals submits NDA for Epanova to the FDA

July 10, 2013

Boehringer Ingelheim discloses novel ACC-beta inhibitors

July 10, 2013

NOX-G16, a new candidate for type 1 diabetes

July 10, 2013

Preclinical data support therapeutic efficacy of UR-1102 for hyperuricemia and gout

July 10, 2013

Lexicon Pharmaceuticals reports data on novel SGLT inhibitors for diabetes

July 10, 2013

Scientists at Receptos synthesize novel GLP-1 receptor modulators

July 9, 2013

Oramed begins patient enrollment in phase IIa trial of ORMD-0801

July 9, 2013

EMA accepts MAA for new insulin glargine biosimilar product

July 9, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...